An alkaline protease mutant with increased stability
By performing specific amino acid mutations and genetic engineering on the alkaline protease of Bacillus lentus, the resulting alkaline protease mutant exhibits excellent stability and catalytic activity under high temperature and high pH conditions. This solves the problem of insufficient stability and pH adaptability of existing alkaline proteases and expands their potential for industrial applications.
Patent Information
- Application Number
- CN202510608083.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-13
- Publication Date
- 2026-11-10
AI Technical Summary
Existing alkaline proteases have shortcomings in terms of stability, pH range adaptability, and hydrolysis efficiency, making it difficult to meet the diverse needs of industrial applications.
By mutating specific amino acids in the alkaline protease of Bacillus lentus, a mutant alkaline protease with increased stability was obtained. This mutant was then expressed in Bacillus licheniformis using genetic engineering methods to optimize its performance under high temperature and high pH conditions.
It significantly improves the stability of alkaline protease mutants in water and their catalytic activity at high temperature and high pH, broadening their application scope in industrial applications, especially in feed processing and detergent manufacturing.
Smart Images

Figure CN123063382A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of enzyme engineering technology, specifically to an alkaline protease mutant with increased stability. Background Technology
[0002] In industrial production, alkaline proteases play a crucial role, often working in synergy with neutral proteases and flavor enzymes to degrade protein macromolecules. The resulting small peptides or free amino acids are widely used in various industries such as feed processing, food manufacturing, leather softening, detergent additives, and pharmaceuticals, and have significant commercial value.
[0003] Alkaline proteases belong to the serine protease family and possess a typical catalytic triplet (Ser-His-Asp) structure, with specific substrate recognition sites near their active sites. While these recognition sites typically only accommodate short peptide chains, the synergistic action of multiple enzyme molecules allows for multi-site binding and cleavage of longer protein chains, thus efficiently breaking down large protein molecules. In an alkaline environment, alkaline proteases efficiently cleave peptide bonds in protein substrates, rapidly reducing the molecular weight and viscosity of the substrates to generate peptides and amino acids. The industrial application conditions for alkaline proteases of different sources and structures vary depending on the characteristics of the target product.
[0004] Currently, various commercially valuable alkaline proteases have been discovered and applied from a variety of microorganisms (such as Bacillus subtilis, Bacillus licheniformis, and Pseudomonas). Among them, alkaline proteases derived from Bacillus lentus and their mutants are widely studied and applied due to their excellent catalytic efficiency and high alkalinity adaptability, occupying an important position in detergents, leather processing, and food processing industries. However, with the continuous development of industry, higher requirements are being placed on alkaline proteases in terms of stability, pH adaptability, and hydrolysis efficiency. Currently, enzyme engineering technology has become an important means of modifying alkaline proteases, focusing on improving stability, expanding pH adaptability, and enhancing hydrolysis efficiency to meet the needs of different application scenarios. To this end, an alkaline protease mutant with increased stability is proposed. Summary of the Invention
[0005] In view of this, the present invention provides an alkaline protease mutant with increased stability. We have found that one of the mutants has higher stability in water compared to the original sequence. This performance is significantly better than that of mainstream alkaline protease products on the market, in order to solve or alleviate the technical problems existing in the prior art, and at least provide a beneficial alternative.
[0006] The technical solution of the present invention is implemented as follows: an alkaline protease mutant with increased stability, wherein the alkaline protease variant is obtained by mutating at least one amino acid from the original sequence of Bacillus lentus alkaline protease, and the most preferred mutant has the amino acid sequence shown in SEQ ID NO:4.
[0007] Further preferably, the full-length coding gene sequence of the original Bacillus lentus alkaline protease is shown in the sequence corresponding to SEQ ID NO.1.
[0008] More preferably, the alkaline protease sequence mutant is obtained by mutating at least one amino acid site in the Bacillus lentus alkaline protease sequence.
[0009] Further preferably, the full-length coding gene sequence of the original Bacillus lentus alkaline protease is shown in SEQ ID NO.1; the corresponding amino acid sequence is shown in SEQ ID NO.2.
[0010] Further preferably, the amino acid sequence of the preferred Bacillus lentus alkaline protease sequence mutant is shown in SEQ ID NO.4.
[0011] Further preferably, the nucleotide coding sequence of the alkaline protease sequence mutant is as shown in SEQ ID NO.3.
[0012] A further preferred embodiment is an expression vector for expressing the alkaline protease sequence mutant of the present invention, which contains the gene encoding the Bacillus lentus alkaline protease sequence mutant of the present invention.
[0013] More preferably, the expression vector comprises an expression component consisting mainly of a natural or synthetic promoter sequence, a natural or synthetic ribosome binding site, a natural or synthetic terminator sequence, and the gene sequence encoding the Bacillus lentus alkaline protease mutant as described in this invention.
[0014] Further preferably, a recombinant cell for expressing the Bacillus lentus alkaline protease variant of the present invention contains one or more genes encoding the preferred Bacillus lentus alkaline protease mutant of the present invention.
[0015] Further preferred, the host cell for the recombinant cells is preferably a Bacillus strain, further preferred is Bacillus licheniformis or other Bacillus strains that have been genetically engineered to inactivate some endogenous proteins; most preferred is Bacillus licheniformis that has been genetically engineered to inactivate the AprE and / or BlasE genes.
[0016] The embodiments of the present invention have the following advantages due to the adoption of the above technical solutions:
[0017] This invention, through specific amino acid mutations in the alkaline protease of Bacillus tarda, yields an alkaline protease mutant with significantly improved stability in water and excellent performance under high temperature and high pH conditions. This mutant has broad application prospects in industrial fields such as feed processing and detergent manufacturing, providing strong technical support for the development of related industries. Furthermore, the genetic engineering and fermentation production methods employed in this invention offer advantages such as high operability and high yield, facilitating the large-scale industrial production of the alkaline protease mutant.
[0018] The above overview is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features of the invention will become readily apparent from the accompanying drawings and the following detailed description. Attached Figure Description
[0019] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0020] Figure 1 The diagram below illustrates the pYF-ts000 vector of this invention: The pYF-ts000 vector is a thermosensitive E. coli / B. licheniformis shuttle plasmid, containing a temperature-sensitive element (with replication activity at 30°C) and an erythromycin-determining gene (ErmC). In E. coli, the tolerance concentration to erythromycin is 300 μg / mL; in Bacillus licheniformis, the tolerance concentration is 5 μg / mL. This vector is used to screen recombinant host cells containing nucleotide sequences encoding alkaline protease mutants.
[0021] Figure 2A schematic diagram of the pYF-tsINT-StablePro vector of the present invention shows the construction method and structure of the pYF-tsINT-StablePro vector. This vector is used to integrate the alkaline protease mutant expression cassette into the AmyE site of the Bacillus licheniformis genome to ensure stable expression of the mutant gene.
[0022] Figure 3 The enzymatic temperature reaction curves of this invention are shown below: the enzyme activities of the original alkaline protease and the alkaline protease mutant of this invention were compared at different temperatures. The results show that the mutant has the highest enzyme activity at 65℃, while the original protease has the highest enzyme activity at 55℃, and the mutant has significantly better stability at high temperatures than the original protease.
[0023] Figure 4 The enzymatic pH reaction curves of this invention show the changes in enzyme activity of the original alkaline protease and the mutant under different pH conditions. The mutant exhibits the highest catalytic activity under alkaline conditions at pH 10.5, and maintains high enzyme activity and good catalytic performance over a wide alkaline range from pH 10 to pH 12, slightly better than the original sequence. Detailed Implementation
[0024] In the following description, only certain exemplary embodiments are briefly described. As those skilled in the art will recognize, the described embodiments can be modified in various ways without departing from the spirit or scope of the invention. Therefore, the drawings and description are considered to be exemplary in nature and not restrictive.
[0025] The embodiments of the present invention will now be described in detail with reference to the accompanying drawings.
[0026] Example 1: Construction of pYF-ts000 plasmid
[0027] pYF-ts000( Figure 1 This is a thermosensitive E. coli / B. licheniformis shuttle plasmid. The plasmid consists of a temperature-sensitive origin of replication (active at 30°C) and an erythromycin resistance gene (ErmC), which provides resistance of 300 μg / ml in E. coli and 5 μg / ml in B. licheniformis. At 37°C, the origin of replication on the plasmid is inactivated, and the plasmid integrates into the designated site in the host bacterial genome, followed by selection using ErmC.
[0028] The construction process of the pYF-tsDE plasmid is as follows: the plasmid pUC57-YF-erm (preserved in our laboratory) was double-digested with BglII, the 3.8kbp fragment was recovered and purified, and self-ligated using T4 ligase (provided by NEB). The cloned plasmid is pYF-tsDE. The transformant was propagated in E. coli TOP10 and used as the backbone for all subsequent gene manipulations.
[0029] Example 2: Construction of a protease-deficient B. licheniformis strain
[0030] Genetically engineered bacterial strains used as host cells for recombinant enzyme products have been reported in the literature (Widner et al., Journal of Industrial Microbiology & Biotechnology, 25, 204-212, 2000). These recombinant host cells generally contain one or more nucleic acid structures encoding the target sequence for enzyme expression. In this invention, *Bacillus licheniformis* is used as the recipient bacterium for gene manipulation. Transformation of *Bacillus* can currently be achieved through well-established methods such as competent cell transformation, electroporation, and protoplast transformation (Young et al., J Bacteriology, ...).
[0031] 81, 823-829, 1961; Shigekawa et al., Biotechniques, 6, 742-751, 1988; Changet al., Molecular General Genetics, 168, 111-115, 1979).
[0032] In this invention, a single alkaline protease mutant expression cassette comprises a natural or synthetic promoter sequence, a signal peptide sequence screened from Bacillus, a synthetic ribosome binding site, an alkaline protease mutant coding gene from B. lentus, and a transcription terminator. This design significantly enhances gene expression levels and the secretion of the alkaline protease mutant in the host strain. The replacement of a specific site on the B. licheniformis cell genome with the alkaline protease mutant coding gene is achieved through plasmid-mediated single crossover homologous recombination.
[0033] In *B. licheniformis*, the activity of extracellular proteases is detrimental to the secretion of heterozygotes. Two major extracellular proteases have been identified: subtilisin (AprE) and glutamic acid-specific protease (Blase). Most of the extracellular protease activity in *B. licheniformis* originates from these two proteases.
[0034] In this invention, to obtain the structural integrity of the alkaline protease mutant gene expression, the two genes mentioned above are inactivated using a continuous single-crossover Campbellian mechanism. The specific operation is as follows:
[0035] pYF-tsDE was digested with BglII and then treated with CIP to inhibit self-ligation;
[0036] Gene knockout
[0037] To obtain the deleted gene fragments, approximately 500 bp homologous sequences were amplified from both sides of the gene to be deleted using PCR, with *Bacillus subtilis* genomic DNA as a template. Single clones of *Bacillus subtilis*, after pre-denaturation at 98°C for 5 minutes, could be used directly as genomic DNA templates in the PCR reaction.
[0038] The primers used for the PCR reaction were synthesized by Qingke Biotechnology. The primer sequences are as follows:
[0039] The primers for amplifying the upstream sequence of the Apr gene are:
[0040] lichApr_F1 TTATTGAGCGGCAGCTTCGACATTGATCAGACCTT
[0041] lichApr_R1 CCTTACGGCATTCCTCTCAACAGCGGATCTTCAG
[0042] The primers for amplifying the downstream sequence of the Apr gene are:
[0043] lichApr_F2 CCTGAAGATCCGCTGTTGAGAGGAATGCCGTAAGG
[0044] lichApr_R2 ATGATGAGGAAAAAGAGTTTTTGGCTTGGGATGCTGAC
[0045] The primers for amplifying the upstream sequence of the Blase gene are:
[0046] blalich_F1 TTATTGTGCGCTGTTTTTCCAGTTGGTCAAATTGTCG
[0047] blalich_cR1 CGGACAAGGGTCACCAACGGGACAACTGTTACCATC
[0048] The primers for amplifying the downstream sequence of the Blase gene are:
[0049] blalich_cF2 GATGGTAACAGTTGTCCCGTTGGTGACCCTTGTCC
[0050] blalich_R2 CGGCGTTGGTTAGTAAAAAGAGTGTTAAACGAGGTTTGAT
[0051] The PCR amplification system consisted of 50 μL, and the reaction procedure was as follows:
[0052] Bacillus subtilis licheniformis 14580 monoclonal pre-denaturation at 98°C for 8 minutes;
[0053] 96℃, 15 seconds;
[0054] 58℃, 15 seconds;
[0055] 72℃, 30 seconds; repeat steps 2-4 25-30 times;
[0056] Finally, extend to 72℃ for 2 minutes.
[0057] The PCR products were detected by 0.8% agarose gel electrophoresis and then purified using an Aspirin kit.
[0058] Overlap PCR method amplifies target genes with approximately 400-500 bp of internal sequence deletion.
[0059] The deleted gene fragments were obtained using overlap extension PCR (SOE), and the specific procedure is as follows:
[0060] The upstream and downstream PCR fragments of each gene were recovered and purified separately.
[0061] Using a 1:1 molar ratio of upstream and downstream homologous sequence fragments of each target gene as a template, primer XXCZ-
[0062] F1 and XX-CZ-R2 ("XX" represents Apr or Blase) PCR amplification yields the AprE gene or Blase gene with internally deleted fragments.
[0063] The aforementioned fragments were then recombined using Gibson Assembly (provided by NEB) into the BglII-linearized pYF-tsDE vector, resulting in recombinant plasmids named pYF-ts-Apr and pYF-ts-Blase, respectively. These recombinant plasmids are temperature-sensitive, containing the Apr or Blase gene with approximately 400-500 bp of internal sequence deletion relative to the complete gene.
[0064] The substitution of different alleles can be achieved through homologous recombination, or other well-known homologous recombination methods in the field can be used.
[0065] plasmid transformation
[0066] The method and screening process for transforming knockout plasmids into competent Licheniformis cells in this experiment are as follows:
[0067] Transform Bacillus licheniformis (CICC 22794, purchased from China Microbial Culture Collection) competent cells with the thermosensitive plasmid pYF-ts-Apr or pYF-ts-Blase;
[0068] Positive clone strains were screened for erythromycin resistance using LB medium (containing 10g peptone, 5g yeast extract, and 10g sodium chloride per liter) at 30°C.
[0069] The positive clone strains are then transferred to a 37°C environment for culture, allowing the temperature-sensitive plasmid to fuse into the host genome. To ensure gene substitution at the designated site, several clones are simultaneously inoculated into 2×YT medium and cultured continuously for 24 hours before being subcultured again. The entire process involves 4-5 subcultures (generally requiring 5-7 days).
[0070] Erythromycin-sensitive Bacillus licheniformis cells were screened for PCR identification. Simultaneously, clear hydrolysis zones could be observed on LB agar plates containing 1% skim milk; knockout strains should show significantly reduced hydrolysis zones.
[0071] PCR primers used for identification:
[0072] AprE: Apr-seqF1 / Apr-seqR3
[0073] Blase: Blase-seqF1 / Blase-seqR3
[0074] Apr-seqF1:GCCAGGTTGAAGCGGTCTATTCAT
[0075] Apr-seqR3:TACGGCCATCCGACCATAATGGAAC
[0076] Blase-seqF1:GAAGAGCCGGTCACAATTGC
[0077] Blase-seqR3:GGCCGTTAGATGTGACAGCC
[0078] Example 3: Integration and Construction of Alkaline Protease Mutant Strains
[0079] Construction of alkaline protease mutant expression framework
[0080] The integration plasmid was constructed using the same method as the pYF-tsDE plasmid described above. To integrate the expression cassette into the designed AmyE site on the genome, approximately 800 bp homologous regions were designed upstream and downstream of the AmyE site and linked to both sides of an alkaline protease mutant expression cassette. Simultaneously, several naturally selected bacterial chromosomal DNA fragments and functional synthetic sequences, all essential for controlling the expression of the alkaline protease mutant gene, were assembled.
[0081] A typical alkaline protease mutant expression cassette
[0082] The plasmid consists of the following elements: a natural or synthetic promoter sequence (SEQ ID NO. 5), a synthetic ribosome binding site (aggggaggag), an alkaline protease mutant encoding gene derived from *B. lentus* (SEQ ID NO. 3), and a synthetic termination sequence (SEQ ID NO. 6). A natural signal sequence (SEQ ID NO. 7) is inserted upstream of the alkaline protease mutant encoding gene promoter to enhance the secretion efficiency of the expressed enzyme. The complete alkaline protease mutant expression cassette is inserted into the BglII site of the linearized pYFts000 using Gibson Assembly, and the resulting thermosensitive integrative plasmid is named pYF-tsINT-StablePro( Figure 2 The above sequences were synthesized by Qingke Biotechnology, and then seamlessly cascaded together to obtain the alkaline protease mutant expression cassette. The signal peptide sequence used in this cassette is a natural alkaline protease signal peptide, which can effectively enhance the secretion of the alkaline protease mutant.
[0083] plasmid transformation
[0084] The entire alkaline protease mutant expression cassette (including upstream and downstream homologous fragments of the amyE gene) was circularized using recombination technology into the linearized BglII pYF-ts000 plasmid, thus constructing a thermosensitive plasmid.
[0085] The plasmid, named pYF-tsINT-StablePro, was used to transform *Bacillus licheniformis* strains (CICC 22794, purchased from the China Microbial Culture Collection) lacking the AprE and Blase protease genes. The expression cassette of the alkaline protease mutant without antibiotic resistance markers replaced AmyE. Using this method, the strain successfully integrated the alkaline protease mutant coding gene into the *B. licheniformis* chromosome produced a clear zone on 1% skim milk plates. PCR further confirmed that the expression cassette was integrated into the AmyE site of the recipient strain.
[0086] The engineered strain of B. licheniformis that produces an alkaline protease mutant was stored at -80°C.
[0087] Example 4: Shake-flask fermentation of alkaline protease mutant
[0088] Take an activated bacterial single clone (containing an alkaline protease mutant expression cassette) and inoculate it into 20 ml of culture medium (containing 4.0% maltose syrup, 2.0% peptone, 0.1% yeast extract, 0.6% KH2PO4, and the corresponding antibiotics) and culture it to the logarithmic growth phase. Take 1.2 ml of the culture and inoculate it into 30 ml of culture medium (containing 12.0% maltose syrup, 1.0% peptone, 1% yeast extract, 0.2% KH2PO4, and 0.003% MnCl2), and culture it in a reciprocating shaker at 120 rpm for 3 days. Take 1 ml samples at 24 hours, 48 hours, and 72 hours, centrifuge at 1000 rpm for 1 min, and save the supernatant.
[0089] Example 5: Stepwise fed-batch fermentation process of alkaline protease mutant
[0090] The genetically engineered *B. licheniformis* strain obtained in Example 3 and frozen at -80℃ was streaked onto an agar slant and incubated overnight at 37℃. The agar slant formulation was as follows: 1% peptone, 0.5% yeast extract, 1% NaCl, and 2% agar powder.
[0091] First, several fresh clones were selected and cultured in seed shake flasks containing 50 ml of culture medium at 37°C for 16 hours. The seed shake flask formulation was: 4.0% maltose syrup, 2.0% peptone, 0.1% yeast extract, and 0.6% KH₂PO₄. After 16 hours, all the seed fermentation broth was transferred to a 7L stainless steel fermenter containing 4L of culture medium and fermented for 12 hours at 37°C, with a stirring speed of 350 rpm and an aeration rate of 650 L / H. The fermenter formulation was: 6.0% maltose syrup, 1.0% peptone, 1% yeast extract, 0.2% KH₂PO₄, and 0.003% MnCl₂. Then, the fermentation pH was controlled at approximately 5.7 ± 0.2 with 5% phosphoric acid, and feed was continuously added to the fermenter at a rate of 1 L / 18hrs for the first 18 hours and 0.5 L / 18hrs for the next 110 hours. The feed formulation was: 48% maltose syrup, 6% peptone, and 8% yeast extract. The entire fermentation process lasted 140-150 hours. All culture medium in the fermenter was collected and centrifuged at 4°C, 1010 rpm for 30 minutes. The supernatant after centrifugation was used for alkaline protease mutant enzyme activity analysis.
[0092] Example 6: Alkaline protease activity assay (GB / T 23527-2009)
[0093] The alkaline protease activity was determined using the Folin-Ciocalteu method. Protease activity is defined as the production of 1 μg of tyrosine from 1 g of solid enzyme powder (or 1 mL of liquid enzyme) hydrolyzed in casein for 1 minute at pH 10.5 and 40°C. This is expressed as u / g (or u / mL). Tyrosine, tryptophan, and other phenolic substances, under alkaline conditions, are reduced by Folin-Ciocalteu reagent to produce a blue substance. The absorbance is measured at 680 nm using a spectrophotometer to calculate the enzyme activity.
[0094] Example 7: Enzymatic Properties Analysis of Alkaline Protease
[0095] Enzyme-catalyzed temperature reaction curve:
[0096] Unless otherwise specified, solution preparation and sample testing shall be performed in accordance with the above-described testing procedures.
[0097] Weigh 2.000g of sample, accurately add 100mL of buffer solution and stir for 20min. Take the filtered clear liquid and dilute it to the predetermined range for detection. Set the water bath to (30℃, 35℃, 40℃, 45℃, 50℃, 55℃, 60℃, 65℃, 70℃) respectively, and then detect the enzyme activity of the preheated samples at each temperature point according to the method.
[0098] Experimental results show that the alkaline protease mutant modified by this invention (SEQ ID NO:4) exhibits the highest enzyme activity at 65℃, indicating that its optimal reaction temperature is 65℃. In contrast, the optimal reaction temperature of the original alkaline protease sequence (SEQ ID NO:2) is only 55℃. Further testing revealed that the activity of the original sequence rapidly decreases at temperatures above 55℃, especially at 70℃ and above, where its enzyme activity loss exceeds 80%, exhibiting significant thermal instability. The mutant provided by this invention, however, maintains good catalytic activity at higher temperatures, demonstrating significantly better thermostability than the original sequence, thus fully validating the effectiveness of mutation design in improving enzyme thermostability.
[0099] Enzyme-catalyzed pH reaction curve
[0100] Unless otherwise specified, solution preparation and sample testing shall be performed in accordance with the above-described testing procedures.
[0101] pH buffer: Buffer solutions with different pH values (6.0, 7.0, 8.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0) are obtained by adjusting the mixing ratio of salt and acid in the buffer solution;
[0102] 1. Sample preparation: Weigh 2.000g of sample, accurately add 100mL of buffer solution and stir for 20min. Take the filtered clear liquid and dilute it to the predetermined range with buffer solutions of different pH values for detection.
[0103] Substrate preparation: Prepare substrates with different pH values (6.0, 7.0, 8.0, 9.0, 10.0, 10.5, 11.0, 11.5, 12.0) to participate in the reaction.
[0104] Experimental results show that the alkaline protease mutant obtained by the present invention (corresponding to sequence number SEQ ID NO:4) exhibits the highest catalytic activity under alkaline conditions at pH 10.5, and its optimal reaction pH is slightly higher than that of the original alkaline protease (corresponding to sequence number SEQ ID NO:2). Comparative experiments further confirmed that the optimal reaction pH of the original protease is 10, and its enzyme activity significantly decreases at pH values above 10.5, exhibiting poor high-alkaline stability. In contrast, the mutant provided by the present invention maintains high enzyme activity and good catalytic performance over a wide alkaline range from pH 10 to pH 12, a characteristic slightly superior to the original sequence.
[0105] Stability test
[0106] To investigate the stability of proteases in water, the enzyme solution was diluted with tap water to 400 U / mL, then placed at room temperature. The activity of the proteases was measured every 7 days, and the stability of proteases with different sequences was compared.
[0107] The enzyme activity assay method was GB / T 23527-2009, and the stability results are as follows.
[0108]
[0109] The above results fully demonstrate that the targeted mutation design of the present invention has successfully improved the adaptability and stability of alkaline protease in water, thereby expanding its potential application value in industrial applications.
[0110] In summary, based on a series of experimental data obtained from this invention, it can be clearly concluded that the modified and optimized alkaline protease mutant (SEQ ID NO:4) exhibits excellent application performance under both high temperature and high pH conditions. Specifically, the mutant reaches its optimal catalytic activity at 65°C, which is 10°C higher than the optimal temperature of 55°C for the original protease (SEQ ID NO:2), demonstrating good heat resistance. Particularly noteworthy is that the mutant maintains high catalytic activity in water, while the activity of the original protease rapidly decreases by more than 45% within 28 days, while the catalytic activity of the mutant remains almost unchanged, exhibiting significant stability.
[0111] The above experimental results fully verify the scientific nature and effectiveness of the mutation strategy adopted in this invention. The obtained mutants have a stability that is much better than the original sequence, which greatly expands their potential for industrial application in feed processing, detergents, textile treatment and other applications requiring high temperature and high alkali conditions.
[0112] The embodiments of this invention, in addition to employing technical methods within the art, are inseparable from the guidance of the inventive spirit. Therefore, this invention is not limited to the specific embodiments disclosed, but also covers the revised provisions within the spirit and scope of this invention, as detailed in the claims.
[0113] sequence list
[0114] SEQ ID NO:1
[0115] The original full-length coding gene sequence of the alkaline protease of Bacillus lentus
[0116]
[0117] SEQ ID NO:2
[0118] The original amino acid sequence of the alkaline protease of Bacillus lentus.
[0119] MKKPLGKIVASTALLISVAFSSSIASAAEEAKEKYLIGFNEQEAVSEFVEQVEANDEVAILSEEEEVEIELLHEFETIPVLSVELSPEDVDALELDPAISYIEEDAEVTTMAQSVPWGISRVQAPAAHNRGLTGSGVKVAVLDTGISTHPDLNIRGGASFVPGEPSTQDGNGHGTHVAGTIAALNNSIGV LGVAPSAELYAVKVLGASGSGSSVSSIAQGLEWAGNNGMHVANLSLGSPSPSATLEQAVNSATSRGVLVVAASGNSGAGSISYPARYANAMAVGATDQNNNRASFSQYGAGLDIVAPGVNVQSTYPGSTYASLNGTSMATPHVAGAAALVKQKNPSWSNVQIRNHLKNTATSLGSTNLYGSGLVNAEAATR
[0120] SEQ ID NO:3
[0121] Preferred nucleotide coding sequence of alkaline protease mutant
[0122]
[0123] SEQ ID NO:4
[0124] Preferred amino acid sequence of alkaline protease mutant
[0125] MKKPLGKIVASTALLISVAFSSSIASAAEEAKEKYLIGFNEQEAVSEFVEQVEANDEVAILSEEEEVEIELLHEFETIPVLSVELSPEDVDALELDPAISYIEEDAEVTTMAQTVPWGISRVQAPAAHNRGLTGSGVKVAVLDTGISTHPDLRIRGGASFVPGEPSTQDGNGHGTHVAGTIAALDNSIGV LGVAPNAELYAVKVLGASGSGSSVSSIAQGLEWAGNNMMHVANLSLGLQAPSATLEQAVNSATSRGVLVVAASGNSGAGSISYPARYANAMAVGATDQNNERASFSQYGAGLDIVAPGVNILSTWPGSTYASLNGTSMATPHVAGAAALVKQKNPSWSNVQIRNHLKNTATSLGDTWEYGSGLVNAEAATR
[0126] SEQ ID NO:5
[0127] Synthesized promoter sequence
[0128] ggctgaagaagtggatcgattgtttgagaaaagaagaagaccataaaaataccttgtctgtcatcagacagggtattttttatgctgtccagactgtccgctgtgtaaaaaataggaataaaggggggttgacattattttactgatatgtataatataatttgtataagaaaatgagagctctcgaaacgtaagatgaaaccttagataaaagtgctttttttgttgcaattgaagaattattaatgttaagcttaattaaagataatatctttgaattgtaacgcccctcaaaagtaagaactacaaaaaaagaatacgttatatagaaatatgtttgaaccttcttcagattacaaatatattcggacggactctacctcaaatgcttatctaactatagaatgacatacaagcacaaccttgaaaatttgaaaatataactaccaatgaacttgttcatgtgaattatcgctgtatttaattttctcaattcaatatataatatgccaatacattgttacaagtagaaattaagacacccttgatagccttactatacctaacatgatgtagtattaaatgaatatgtaaatatatttatgataagaagcgacttatttataatcattacatatttttctattggaatgattaagattccaatagaatagtgtataaattatttatcttgaaaggagggatgcctaaaaacgaagaacattaaaaacatatatttgcaccgtctaatggatttatgaaaaatcattttatcagtttgaaaattatgtattatgat
[0129] SEQ ID NO:6
[0130] Synthetic termination sequence
[0131] cgccaaaaaagctgtcctcccctcgttggggtcggacagctttttttatgcgatggaatggctgtcagccgattcgagatctacgcgaacattccg
[0132] SEQ ID NO:7
[0133] native signal sequence
[0134] atgaagaaaccgttggggaaaattgtcgcaagcaccgcactactcatttctgttgcttttagttcatcgatcgcatcggct
[0135] Unless otherwise specified, all technical and scientific terms have the same meaning in this invention and are generally understood as general technical terms. In this application, certain terms have the same meaning as described in the specification. It must be noted that, as used herein and in the appended claims, the singular forms “an” and “this” include the plural forms, unless the context clearly specifies otherwise.
[0136] In this invention, protease refers to an enzyme capable of hydrolyzing proteins or polypeptides. For example, alkaline protease can break down protein stains such as bloodstains or food residues on clothing.
[0137] In this invention, the term "primitive alkaline protease" refers to a naturally occurring alkaline protease. Natural alkaline proteases are bacterial alkaline proteases, and their sources include, but are not limited to, *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus pseudalcalophilus*, and *Bacillus lentus*.
[0138] According to a preferred embodiment of the present invention, the natural alkaline protease is derived from Bacillus strains—especially Bacillus lentus. The full-length coding sequence of the Bacillus lentus alkaline protease is shown in SEQ ID NO.1; the corresponding amino acid sequence is shown in SEQ ID NO.2.
[0139] In this invention, the term "alkaline protease mutant" refers to an alkaline protease that is not naturally occurring and has one or more amino acid residues added, deleted, and / or substituted at effective sites in the original alkaline protease amino acid sequence, while still retaining the original ability to hydrolyze proteins or peptides.
[0140] This invention relates to "alkaline protease mutants" obtained by sequence modification of primitive alkaline proteases. Primitive alkaline proteases are natural alkaline proteases, particularly those derived from bacteria. According to embodiments of the invention, the alkaline protease mutant is obtained by mutating one or more amino acid sites in the effective amino acid sequence of the primitive alkaline protease.
[0141] This invention includes a series of alkaline protease mutants. According to embodiments of the invention, the amino acid sequence homology of this series of alkaline protease mutants is at least 95%, specifically 95%, 96%, 97%, 98%, 99%, or 100%.
[0142] As an illustrative and non-limiting example of the invention, the alkaline protease mutant is obtained by mutating at least one amino acid from the original sequence of Bacillus lentus alkaline protease, and the most preferred mutant has the amino acid sequence shown in SEQ ID NO.4.
[0143] The alkaline protease mutants in this invention retain the ability to hydrolyze proteins or peptides. Furthermore, these alkaline proteases meet the performance requirements of industrial production, for example, exhibiting stable catalytic activity under high temperature and / or high pH conditions.
[0144] This invention provides an alkaline protease mutant capable of hydrolyzing peptide bonds in proteins or polypeptides under suitable temperature and pH conditions for industrial production. According to the invention, the high temperature is preferably 65°C; the high pH is preferably 10.5, making it suitable for the feed and detergent industries.
[0145] On the other hand, the expression vector of the present invention comprises a synthetic nucleotide sequence encoding an alkaline protease mutant, and the recombinant host cell contains the aforementioned expression vector. The expression vector contains a synthetic nucleotide sequence encoding a different alkaline protease mutant. The expression vector can integrate into the genome of the host cell. For example, the expression vector contains a synthetic nucleotide sequence SEQ ID NO.3.
[0146] The expression vector of this invention preferably includes a natural or synthetic promoter sequence, a natural or synthetic ribosome binding site, and a natural or synthetic terminator sequence. These genetic elements, together with the synthetic alkaline protease mutant coding sequence, constitute an expression component, which, together with the vector backbone, forms the expression vector. For example, the expression vector includes an expression component comprising: a promoter sequence, a synthetic ribosome binding site, a synthetic nucleotide sequence encoding the alkaline protease mutant of this invention, and a terminator sequence. The signal sequence can...
[0147] To guide the secretion of alkaline protease mutants, the signal sequence is introduced into the expression vector or expression unit, especially the signal sequence is introduced upstream of the start codon, which is more conducive to the secretion of alkaline protease mutants.
[0148] According to a preferred embodiment of the invention, the expression vector is suitable for expression in bacteria, particularly Bacillus strains, and even more suitable for expression in B. licheniformis. In a particularly preferred embodiment, the expression vector can be integrated into the genome of Bacillus, especially the genome of B. licheniformis. Expression vectors for host cells that can be integrated into chromosomes with polynucleotide sequences, and methods for constructing such expression vectors, are common skills well-known in contemporary biology.
[0149] According to embodiments of the present invention, recombinant host cells can be genetically engineered to contain nucleic acid sequences expressing one or more alkaline protease mutant genes. Any technique can be used to genetically engineer host cells to contain nucleic acid sequences encoded by one or more alkaline protease mutants of the present invention, for example, chromosomal integration. Vectors containing temperature-sensitive origin and resistance selection markers can be used in the integration step. These vectors integrate with specific regions of the genome via the Campbell's mechanism, and recombinant bacteria are obtained through resistance selection. The recombinant bacteria then lose the resistance selection markers through homologous recombination during subsequent culture.
[0150] According to embodiments of the present invention, recombinant host cells are genetically engineered to inactivate certain endogenous proteins. Inactivable endogenous proteins include, but are not limited to, extracellular proteases. Some endogenous proteins are inactivated before or after the recombinant host cells are transformed with a nucleic acid sequence containing an alkaline protease mutant expression gene. A more suitable method is to inactivate exogenous secreted proteases of the host bacteria before introducing the vector containing the alkaline protease mutant expression gene.
[0151] First, Bacillus licheniformis has been modified to inactivate some exogenous protease genes. In particular, the Bacillus licheniformis strain can inactivate some extracellular proteases, such as subtilisin (AprE) and glutamic acid specific protease (Blase). These genetic engineering modifications make the B. licheniformis strain more suitable for the expression and secretion of alkaline protease mutants.
[0152] This invention provides a method for producing an alkaline protease mutant. According to embodiments of the invention, the method includes culturing a recombinant host cell containing a nucleotide sequence encoding the alkaline protease mutant under suitable conditions for alkaline protease mutant expression, and obtaining the alkaline protease mutant from the recombinant host cell or its supernatant.
[0153] All recombinant host cells of this invention are capable of producing alkaline protease mutants. The recombinant host cells contain at least one copy of the nucleotide sequence encoding the alkaline protease mutant. These nucleotide sequences encoding the alkaline protease mutant are capable of expressing the alkaline protease mutant under suitable conditions. The alkaline protease mutant secreted from the recombinant host cells can be collected from the recombinant cells or supernatant. Collection methods include, but are not limited to, filtration, centrifugation, etc.
[0154] According to embodiments of the present invention, genetically engineered Bacillus licheniformis can produce high yields of alkaline protease mutants through fermentation. Bacillus licheniformis has been genetically engineered to introduce a nucleotide sequence encoding the alkaline protease mutant. More importantly, the Bacillus licheniformis of the present invention has had its resistance selection gene removed, making it environmentally friendly and producing alkaline protease mutants more suitable for use in the food and feed industries.
[0155] The following examples further illustrate the essence of this invention. It should be understood that the following examples do not limit the invention, and the scope of the invention is determined by the appended claims.
[0156] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any person skilled in the art can easily conceive of various variations or substitutions within the technical scope disclosed in the present invention, and these should all be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.
Claims
1. A mutant alkaline protease with increased stability, characterized in that: The amino acid sequence of the alkaline protease mutant is derived from the alkaline protease gene of Bacillus tarda. In the mature protease sequence, this mutant contains one or more specific amino acid mutations, specifically S3T, N42R, N74D, S85N, G116M, S126L, P127Q, S128A, N179E, V199I, Q120L, Y203W, S253D, N255W, and L256E. The preferred amino acid sequence of the mutant is shown in SEQ ID NO:
4.
2. The alkaline protease mutant with increased stability according to claim 1, characterized in that: The nucleotide sequence encoding the above-mentioned alkaline protease mutant is shown in SEQ ID NO:
3.
3. The alkaline protease mutant with increased stability according to claim 1, characterized in that: The expression vector for expressing the alkaline protease mutant of the present invention comprises a promoter sequence (SEQ ID NO:5), a natural or synthetic ribosome binding site "aggggaggag", a gene sequence encoding an alkaline protease variant (SEQ ID NO:3), a synthetic terminator sequence (SEQ ID NO:6), and a natural signal sequence inserted upstream of the promoter (SEQ ID NO:7).
4. The alkaline protease mutant with increased stability according to claim 1, characterized in that: The recombinant cells used to express the alkaline protease mutant of the present invention contain the above-described expression vector. The host cell is preferably a genetically engineered Bacillus licheniformis strain with the AprE and / or BlasE genes inactivated. This modification reduces the degradation of the target mutant by endogenous proteases in the host cell, thereby improving the expression and secretion efficiency of the mutant.
5. The alkaline protease mutant with increased stability according to claim 1, characterized in that: The method for producing alkaline protease mutants involves culturing recombinant cells containing gene sequences encoding alkaline protease mutants under suitable alkaline protease variant expression conditions, and then extracting the target protease variant from the cells or their culture supernatant.
